Clinical trials: Ebola Virus Infection
Ebola Virus Disease
EBOVAC-Salone Extension
The VAC52150EBL3005 (EBOVAC-Salone Extension) is a cohort study evaluating the long-term safety and immunogenicity of the candidate Ebola vaccines Ad26.ZEBOV and MVA-BN®-Filo in participants who were exposed to these vaccines in…
- Trial name
- NCT03820739
- Testing
- Follow-up, Blood sample collection
- Where
- 2 sites in Sierra Leone
- Volunteers
- 653 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Ebola Virus Disease
Effectiveness and Safety of a Heterologous, Two-dose Ebola Vaccine in the DRC
A single arm, open-label, non-randomized, interventional phase 3 study to measure safety and effectiveness of a heterologous, two dose preventative vaccine (Ad26. ZEBOV, MVA-BN®-Filo) against Ebola Virus Disease.
- Trial name
- NCT04152486
- Testing
- Ad26.ZEBOV, MVA-BN-Filo vaccine
- Where
- Democratic Republic of the Congo
- Volunteers
- 20,426 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Ebola Virus Disease
Natural History, Disease Progression, and Long-Term Neurologic Sequelae of Ebola Virus Disease (EVD) Survivors in PREVAIL III
Background: Ebola virus disease (EVD) is a viral fever that can cause internal bleeding. The death rate from EVD is very high. In a 2014 outbreak in West Africa, 28,000 were affected and 11,000 died.
- Trial name
- NCT05494801
- Where
- Liberia
- Volunteers
- 203 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Ebola, Ebola Zaire
A Study to Assess New Ebola Vaccines, cAd3-EBO Z and MVA-BN® Filo
The purpose of this study is to assess two new Ebola vaccines: cAd3-EBO Z at 3 different doses, and a second vaccine, MVA-BN® Filo, at 3 different doses.
- Trial name
- NCT02240875
- Testing
- cAd3-EBO Z at 1 x 10^10 vp, cAd3-EBO Z at 2.5 x 10^10 vp, cAd3-EBO Z at 5 x 10^10 vp
- Where
- United Kingdom
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Ebola Virus Disease
Prophylaxis Vaccine Antibodies Ebola
Three measures are currently being implemented to control Ebola outbreaks: Monitoring of contacts Isolation and treatment of sick people Vaccination of the population in high-risk areas.
- Trial name
- PROVAE (NCT04822376)
- Testing
- ansuvimab, Ervebo
- Where
- Guinea
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Ebola Virus Disease
A Phase I Study to Assess Ebola Vaccines cAd3-EBO Z and MVA-EBO Z
This is a clinical trial in which healthy volunteers will be administered experimental Ebola vaccines. The investigators will vaccinate four groups of volunteers.
- Trial name
- NCT02451891
- Testing
- MVA-EBO Z, ChAd3-EBO Z
- Where
- United Kingdom
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Ebola Virus Disease
A Phase I Clinical Trial to Evaluate the Ebola Adenovirus Vector Vaccine (Ad5-EBOV) in Healthy Adults.
Since its first outbreak occurred in 1976, Zaire Ebola virus have been associated with 14 outbreaks reported up to 2014. The Zaire Ebola virus in 2014 causing the most serious outbreak was considered to be a new epidemic strain…
- Trial name
- NCT02326194
- Testing
- Low dose Ebola Zaire vaccine (Ad5-EBOV), High dose Ebola Zaire vaccine (Ad5-EBOV)
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Healthy
A Safety and Immunogenicity Study of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants
The purpose of this study is to test the safety and immunogenicity of MVA-BN-Filo and Ad26.ZEBOV as heterologous prime-boost vaccine regimens in healthy adult participants.
- Trial name
- NCT02313077
- Testing
- MVA-BN-filo, Ad26. ZEBOV
- Where
- United Kingdom
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Ebola Virus Disease
Addressing Medium- to Long-term EBOLA Associated Psychological Distress and Psychosocial Problems in Central Uganda
Screen participants attending 11 healthcare facilities in Mubende District for psychological distress using the locally validated Luganda or English version of the WHO- Self Report Questionnaire (SRQ-20).
- Trial name
- Ebola+D (NCT06093646)
- Testing
- Ebola+D intervention
- Where
- Uganda
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- MRC/UVRI and LSHTM Uganda Research Unit
Ebola Virus Disease
Safety and Immunogenicity of the rVSVΔG-ZEBOV-GP Ebola Virus Vaccine Candidate in Children Living in Lambaréné, Gabon
LA rVSVΔG-ZEBOV-GP -02-PED is a Phase 1/2, randomized, controlled open label trial. The LA rVSVΔG-ZEBOV-GP -02-PED trial aims primarily to assess the clinical significance of shedding of the rVSV RNA following vaccination with…
- Trial name
- EBOLAPED (NCT05130398)
- Testing
- rVSVΔG-ZEBOV-GP, V920, Fibre and equilibrate breakfast and lunch, Active detection and treatment of pathogens
- Where
- Gabon
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Centre de Recherche Médicale de Lambaréné
Ebola Virus Disease, Hemorrhagic Fever
Ebola CVD-Mali #2000 (Bivalent) VRC-EBOAdc069-00-vp (cAd3-EBO)
Ebola virus causes an infection known as Ebola virus disease (EVD). This it is generally a severe disease which can also lead to death. The 2014 outbreak of EVD in West Africa is the largest ever.
- Trial name
- NCT02368119
- Testing
- VRC-EBOADC069-00-vp, MVA-EbolaZ
- Where
- Mali
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Ebola Virus Disease
An Open-Label Study , Safety and Tolerability of Brincidofovir for Post Exposure Prophylaxis of Ebola
The purpose of this study is to determine how safe and tolerable Brincidofovir (BCV) is when given for post exposure prophylaxis of Ebola virus disease.
- Trial name
- BCV EBOV (NCT04268966)
- Testing
- Brincidofovir
- Sponsor
- Jazz Pharmaceuticals
Ebola Hemorrhagic Fever, Ebola Virus Disease
Experimental Vaccine for Prevention of Ebola Virus Infection
This study will determine if an experimental vaccine to prevent Ebola virus infection is safe and what side effects, if any, it causes.
- Conditions
- Ebola Hemorrhagic Fever, Ebola Virus Disease, Ebola Virus Vaccines, Envelope Glycoprotein, Ebola Virus
- Trial name
- NCT00374309
- Testing
- VRC-EBOADV018-00-VP
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Ebola Virus Disease
R3470-3471-3479 (REGN-EB3) Expanded Access Protocol (EAP) for Treatment of Ebola Virus Disease
Provide access to REGN-EB3 for the treatment of patients with Ebola Virus Disease (EVD).
- Trial name
- NCT03576690
- Testing
- REGN3470-3471-3479
- Sponsor
- Regeneron Pharmaceuticals
Hemorrhagic Fever, Ebola, Healthy
Experimental Ebola Vaccine Trial
This study will test the safety of an experimental vaccine developed to protect against Ebola virus infection and to determine if the vaccine induces an immune response to the virus.
- Trial name
- NCT00072605
- Testing
- VRC-EBODNA012-00-VP
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Ebola Virus Infection
Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study of Intravenous (IV) TKM-100201 Infusion
This is a phase 1, single-center, placebo-controlled, single-blind, first-in-human, single-ascending dose study with additional multiple-ascending dose cohorts in healthy male and female volunteers.
- Trial name
- NCT01518881
- Testing
- TKM-100201
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Arbutus Biopharma Corporation
Ebola Hemorrhagic Fever, Bundibugyo Virus Disease
Study of Vaccines Against Bundibugyo Virus Disease in Contacts of Cases in the Democratic Republic of the Congo
Bundibugyo virus (BDBV) causes severe and often fatal outbreaks of Bundibugyo virus disease (BVD). No vaccine against BDBV is licensed.
- Trial name
- TUMAINI (NCT07842107)
- Testing
- Candidate BDBV vaccine, Active comparator
- Where
- Democratic Republic of the Congo
- Volunteers
- 3,620 people, healthy volunteers welcome
- Sponsor
- Jean-Pierre Van geertruyden
Cataract
PREVAIL VII: Cataract Surgery in Ebola Survivors
Objective: Zaire ebolavirus is a single-stranded RNA virus associated with high morbidity and mortality. The most recent epidemic of Ebola virus disease (EVD) in West Africa resulted in over 11,000 deaths and disabling sequelae…
- Trial name
- NCT03309020
- Testing
- Cataract surgery
- Where
- Liberia
- Volunteers
- 37 people
- Sponsor
- National Eye Institute (NEI)
Ebola Virus Disease
INO-4201 as Booster in Healthy VSV-ZEBOV Vaccinees
Ebola virus disease (EVD) is a serious illness with a high fatality rate. Currently only one vaccine is available, VSV-ZEBOV/Ervebo; this vaccine is clinically effective and has been deployed as a preventive measure during recent…
- Trial name
- Boost-EBOV (NCT04906629)
- Testing
- INO-4201
- Where
- Switzerland
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- University of Geneva, Switzerland
Ebola Virus Disease
Evaluation of a New Ebola Vaccine Using a Short-interval Prime-boost Vaccination
This is a clinical trial in which healthy volunteers will be administered two experimental Ebola vaccines: ChAd3-EBO Z and MVA-EBO Z.
- Trial name
- NCT02485912
- Testing
- ChAd3-EBO Z, MVA-EBO Z
- Where
- Senegal
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Oxford